These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19834626)

  • 1. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.
    Tzschentke TM; Jahnel U; Kogel B; Christoph T; Englberger W; De Vry J; Schiene K; Okamoto A; Upmalis D; Weber H; Lange C; Stegmann JU; Kleinert R
    Drugs Today (Barc); 2009 Jul; 45(7):483-96. PubMed ID: 19834626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tapentadol hydrochloride: a centrally acting oral analgesic.
    Wade WE; Spruill WJ
    Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
    Hartrick CT
    Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapentadol (Nucynta)--a new analgesic.
    Med Lett Drugs Ther; 2009 Aug; 51(1318):61-2. PubMed ID: 19661853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapentadol - A representative of a new class of MOR-NRI analgesics.
    Zajączkowska R; Przewłocka B; Kocot-Kępska M; Mika J; Leppert W; Wordliczek J
    Pharmacol Rep; 2018 Aug; 70(4):812-820. PubMed ID: 29921501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
    Tzschentke TM; Christoph T; Schröder W; Englberger W; De Vry J; Jahnel U; Kögel BY
    Schmerz; 2011 Feb; 25(1):19-25. PubMed ID: 21258822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
    Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
    Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
    Schiene K; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
    Tzschentke TM; Christoph T; Kögel BY
    CNS Drugs; 2014 Apr; 28(4):319-29. PubMed ID: 24578192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current considerations for the treatment of severe chronic pain: the potential for tapentadol.
    Pergolizzi J; Alegre C; Blake D; Alén JC; Caporali R; Casser HR; Correa-Illanes G; Fernandes P; Galilea E; Jany R; Jones A; Mejjad O; Morovic-Vergles J; Oteo-Álvaro Á; Radrigán Araya FJ; Simões ME; Uomo G
    Pain Pract; 2012 Apr; 12(4):290-306. PubMed ID: 21797962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is tapentadol an advance on tramadol?
    Guay DR
    Consult Pharm; 2009 Nov; 24(11):833-40. PubMed ID: 20092221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain.
    Schröder W; Vry JD; Tzschentke TM; Jahnel U; Christoph T
    Eur J Pain; 2010 Sep; 14(8):814-21. PubMed ID: 20541444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo characterization of tapentadol metabolites.
    Terlinden R; Kogel BY; Englberger W; Tzschentke TM
    Methods Find Exp Clin Pharmacol; 2010; 32(1):31-8. PubMed ID: 20383344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapentadol for pain: a treatment evaluation.
    Hartrick CT; Rodríguez Hernandez JR
    Expert Opin Pharmacother; 2012 Feb; 13(2):283-6. PubMed ID: 22192161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tapentadol is a new, strongly efficative analgeticum with dual effect mechanisms].
    Staahl C; Drewes AM; Jensen NH
    Ugeskr Laeger; 2011 Jun; 173(25):1796-9. PubMed ID: 21689507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
    Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
    J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.